- BMSystems will participate to BIO in Boston, June 18-21; and Bio-Europe in Hamburg November, 12-14.
- Munich,may 11-12, 2012: BMSystems' CSO François Iris, is invited as session chairman to the 8th International Workshop on Computational Neuropsychiatry: Sleep, Affective disorders and Schizophrenia - An integrated view.
- Press-Release-Feb-2012: Pherecydes Pharma secures a €1.2-million Defense agency funding for evaluating the use of bacteriophages against infected, antibiotic resistant burns.
Downloads
BMSystems European Commission Conference Presentation
The EC "From Systems Biology to Systems Medicine" report
Industrial biotech World cluster
Spin-off sites
BMSystems collaborative Network
BMSystems collaborative scientific and business network (non-confidential extract)
- Pherecydes-Pharma: Antibacterial agents Biodefense & biosecurity spin-off.
- Pharma companies: (confidential).
- Cosmetic companies: (confidential).
- Amarokbiotech: Synthon's program partner
- ARD: (Agro-industries Research & Development) leading Industrial Biotech research company in the industrial biotech world class cluster in France.
- IBT: (Troyes Institute of Biotechnologies). Technological transfer institute.
- CVG: Chemistry company based in Picardie for "green" sourcing research.
- L'Oréal: World leader in the cosmetic market. Synthon's program partner.
- Rhodia: Major actor in the fine chemicals market (former Aventis fine chemical business). Synthon's program partner.
- Arkema: Major actor in the chemistry market (former Total chemical business) Synthon's program partner.
- ACE management: (financière de Brienne & FCPR Security).
- CEA Fontenay-aux Roses: Department of prion and atypical infections research (SEPIA)
- Max Planck Institute of Psychiatry Munich.
- BioPhys-Solutions electro-magnetic applications to aqueous solutions Paris
- Kayentis: The provider of the first "Digital Pen and Paper technology 2.0", the universal platform delivering "contextualized" information.
- Biocitech: Technology Park.
- TheraNexus: Psychiatric disorders treatments based on our collaborative research program with CEA life Sciences.
